Patents by Inventor Aiden Haghikia
Aiden Haghikia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11865091Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.Type: GrantFiled: June 3, 2020Date of Patent: January 9, 2024Assignee: Flexopharm Brain GMBH & Co. KGInventors: Ralf Gold, Aiden Haghikia, Ralf Linker
-
Patent number: 11602510Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.Type: GrantFiled: March 9, 2018Date of Patent: March 14, 2023Assignee: Flexopharm Brain GMBH & Co. KGInventor: Aiden Haghikia
-
Patent number: 11471432Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: GrantFiled: June 29, 2020Date of Patent: October 18, 2022Assignee: Flexopharm Brain GMBH & Co. KGInventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
-
Publication number: 20220313634Abstract: The invention relates to an agent for use in the prophylactic and/or supportive therapeutic treatment of Parkinson's disease, said agent comprising a physiologically effective amount of propionic acid and/or butyric acid and/or physiologically compatible salts or esters thereof.Type: ApplicationFiled: June 20, 2022Publication date: October 6, 2022Inventors: Horst Przuntek, Aiden Haghikia
-
Publication number: 20200323802Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: ApplicationFiled: June 29, 2020Publication date: October 15, 2020Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
-
Publication number: 20200289442Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.Type: ApplicationFiled: June 3, 2020Publication date: September 17, 2020Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ralf Linker
-
Patent number: 10695305Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: GrantFiled: July 8, 2016Date of Patent: June 30, 2020Assignee: FLEXOPHARM BRAIN GMBH & CO. KGInventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
-
Patent number: 10682322Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.Type: GrantFiled: October 19, 2015Date of Patent: June 16, 2020Assignee: FLEXOPHARM BRAIN GMBH & GO. KGInventors: Ralf Gold, Aiden Haghikia, Ralf Linker
-
Publication number: 20200163914Abstract: The invention relates to an agent for use in the prophylactic and/or supportive therapeutic treatment of Parkinson's disease, said agent comprising a physiologically effective amount of propionic acid and/or butyric acidType: ApplicationFiled: July 13, 2018Publication date: May 28, 2020Inventors: Horst Przuntek, Aiden Haghikia
-
Publication number: 20200138875Abstract: The invention relates to an agent for use in the treatment of diseases due to an imbalance of the microbiome, in particular multiple sclerosis (MS) and Parkinson's disease, in the form of a microbiome transplant to be administered to the patient to be treated, wherein the microbiome transplant being obtainable from the stool of one or several healthy subjects through extraction with an aqueous medium, concentration of the extract and packaging to obtain a transplantable concentrate.Type: ApplicationFiled: May 25, 2018Publication date: May 7, 2020Inventors: Horst Przuntek, Aiden Haghikia
-
Publication number: 20200030267Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.Type: ApplicationFiled: March 9, 2018Publication date: January 30, 2020Applicant: Flexopharm Brain GMBH & Co. KGInventor: Aiden Haghikia
-
Publication number: 20180303778Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: ApplicationFiled: July 8, 2016Publication date: October 25, 2018Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
-
Publication number: 20170231933Abstract: The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing C3-C8 carboxylic acids, their physiologically tolerable salts and/or esters with C1-C8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.Type: ApplicationFiled: October 19, 2015Publication date: August 17, 2017Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ralf Linker
-
Publication number: 20150267254Abstract: The invention provides a method of determining if a patient is afflicted with multiple sclerosis (MS) using microRNA (miRNA) profiles of specific miRNAs that are present in the cerebrospinal fluid (CSF). This method can also be used to discriminate different forms of MS. The invention further comprises a kit for diagnosing or monitoring MS based upon the miRNA profiles according to the invention, and also relates to the use of said miRNA profiles in the diagnosis or monitoring of MS.Type: ApplicationFiled: July 5, 2013Publication date: September 24, 2015Applicants: MEDIZINISCHE HOCHSHULE HANNOVER, ST. JOSEF - UND ST. ELISABETH HOSPITAL GMBHInventors: Thomas Thum, Aiden Haghikia, Arash Haghikia, Ralf Gold